Literature DB >> 19727917

Acute generalized exanthematous pustulosis and toxic epidermal necrolysis induced by hydroxychloroquine.

Aisha Lateef1, Kong-Bing Tan, Tang Ching Lau.   

Abstract

Acute generalized exanthematous pustulosis (AGEP) and toxic epidermal necrolysis (TEN) are both severe cutaneous adverse reactions, mostly to drugs. Although predominantly involving skin, they differ significantly in presentations, prognosis, pathology, immunogenesis, and treatment. They have very rarely been described to occur simultaneously in a patient, manifesting as AGEP-TEN overlap. We describe a 67-year-old Chinese lady with systemic lupus erythematosus who presented with features of AGEP but evolved to AGEP-TEN overlap as an adverse reaction to hydroxychloroquine (HCQ) treatment. This case is the first reported case of AGEP-TEN overlap secondary to HCQ and highlights the need for constant surveillance for rare adverse events that may manifest even after decades of use of the drug worldwide.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19727917     DOI: 10.1007/s10067-009-1262-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  9 in total

1.  Fatal toxic epidermal necrolysis associated with hydroxychloroquine.

Authors:  M Murphy; A J Carmichael
Journal:  Clin Exp Dermatol       Date:  2001-07       Impact factor: 3.470

2.  Acute generalized exanthematous pustulosis precipitated by hydroxychloroquine.

Authors:  Colby C Evans; Paul R Bergstresser
Journal:  J Am Acad Dermatol       Date:  2004-04       Impact factor: 11.527

3.  Acute generalized exanthematous pustulosis induced by hydroxychloroquine.

Authors:  A Martins; L C Lopes; M J Paiva Lopes; J C Rodrigues
Journal:  Eur J Dermatol       Date:  2006 May-Jun       Impact factor: 3.328

Review 4.  Toxic epidermal necrolysis.

Authors:  Frederick A Pereira; Adarsh Vijay Mudgil; David M Rosmarin
Journal:  J Am Acad Dermatol       Date:  2007-02       Impact factor: 11.527

5.  Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumour necrosis factor-alpha antibody infliximab: report of three cases.

Authors:  F Meiss; P Helmbold; N Meykadeh; G Gaber; W Ch Marsch; M Fischer
Journal:  J Eur Acad Dermatol Venereol       Date:  2007-05       Impact factor: 6.166

6.  T-cell involvement in drug-induced acute generalized exanthematous pustulosis.

Authors:  M Britschgi; U C Steiner; S Schmid; J P Depta; G Senti; A Bircher; C Burkhart; N Yawalkar; W J Pichler
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

7.  Acute generalised exanthematous pustulosis and toxic epidermal necrolysis induced by carbamazepine.

Authors:  T K Goh; S M Pang; T Thirumoorthy; S G N Goh
Journal:  Singapore Med J       Date:  2008-06       Impact factor: 1.858

8.  Hydroxychloroquine-associated, photo-induced toxic epidermal necrolysis.

Authors:  E L Callaly; O FitzGerald; S Rogers
Journal:  Clin Exp Dermatol       Date:  2008-05-12       Impact factor: 3.470

Review 9.  Acute generalized exanthematous pustulosis induced by hydroxychloroquine: three cases and a review of the literature.

Authors:  Andrea Paradisi; Leonardo Bugatti; Teresa Sisto; Giorgio Filosa; Pier Luigi Amerio; Rodolfo Capizzi
Journal:  Clin Ther       Date:  2008-05       Impact factor: 3.393

  9 in total
  10 in total

1.  Hemophagocytic lymphohistiocytosis after certolizumab treatment in a patient with rheumatoid arthritis.

Authors:  Göksel Güven; Aslıhan Güler; Nil Özyüncü; Leyla Talan; Aylin Heper; Tahsin Murat Turgay; Neriman Defne Altıntaş
Journal:  Eur J Rheumatol       Date:  2018-02-13

2.  Hydroxychloroquine-Induced Erythema Multiforme.

Authors:  Nour Abou Assalie; Robert Durcan; Laura Durcan; Michelle A Petri
Journal:  J Clin Rheumatol       Date:  2017-03       Impact factor: 3.517

3.  Successful Treatment of Hydroxychloroquine-Induced Recalcitrant Acute Generalized Exanthematous Pustulosis with Cyclosporine: Case Report and Literature Review.

Authors:  Başak Yalçın; Seray Çakmak; Betül Yıldırım
Journal:  Ann Dermatol       Date:  2015-07-29       Impact factor: 1.444

4.  Pustular drug eruption due to Panax notoginseng saponins.

Authors:  ZhiQiang Yin; LiWen Ma; JiaLi Xu; JiPing Xia; Dan Luo
Journal:  Drug Des Devel Ther       Date:  2014-07-16       Impact factor: 4.162

Review 5.  Acute Generalized Exanthematous Pustulosis: Pathogenesis, Genetic Background, Clinical Variants and Therapy.

Authors:  Laurence Feldmeyer; Kristine Heidemeyer; Nikhil Yawalkar
Journal:  Int J Mol Sci       Date:  2016-07-27       Impact factor: 5.923

6.  Acute generalized exanthematous pustulosis induced by hydroxychloroquine: a case with atypical clinical presentation.

Authors:  Hatice Duman; Ilteris Oguz Topal; Emek Kocaturk; Kubra Cure; Ilknur Mansuroglu
Journal:  An Bras Dermatol       Date:  2017 May-Jun       Impact factor: 1.896

7.  [Drug-induced toxidermia in a patient receiving hydroxychloroquine as systemic therapy for primary Gougerot-Sjögren syndrome: a case report].

Authors:  Ansumana Mohammed Keita; Mouna Zahlane; Laila Benjilali; Lamiaa Essaadouni
Journal:  Pan Afr Med J       Date:  2021-03-18

8.  Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials.

Authors:  Can Chen; Kunming Pan; Bingjie Wu; Xiaoye Li; Zhangzhang Chen; Qing Xu; Xiaoyu Li; Qianzhou Lv
Journal:  Eur J Clin Pharmacol       Date:  2020-08-11       Impact factor: 2.953

9.  Acute generalized exanthematous pustulosis simulating toxic epidermal necrolysis: case presentation and literature review.

Authors:  Ana-Maria Copaescu; Danielle Bouffard; Marie-Soleil Masse
Journal:  Allergy Asthma Clin Immunol       Date:  2020-02-04       Impact factor: 3.406

Review 10.  Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine.

Authors:  Robert A Schwartz; Camila K Janniger
Journal:  Dermatol Ther       Date:  2020-04-16       Impact factor: 3.858

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.